STEWART C MANNING

Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology ELIZABETH CITY, NC NPI 1104897537

General Payments — all program years on this page

$6,352.40

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 341
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $388.65 across 20 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $388.6520

By paying entity

Latest program year (PY2024) · sorted by reported total.

By program year

Program yearAmountRecords
2018 $1,147.2574
2019 $920.0760
2020 $406.4031
2021 $1,911.5565
2022 $911.3055
2023 $667.1836
2024 $388.6520

Records — PY2024 (20)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1087066612 Novartis Pharmaceuticals Corporation $22.41 02/21/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1087066614 Novartis Pharmaceuticals Corporation $17.24 04/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1087066624 Novartis Pharmaceuticals Corporation $16.81 06/20/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1087066630 Novartis Pharmaceuticals Corporation $25.54 08/20/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104206049 AstraZeneca Pharmaceuticals LP $16.40 10/02/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104239583 AstraZeneca Pharmaceuticals LP $23.00 05/30/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104533288 AstraZeneca Pharmaceuticals LP $19.93 02/07/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104959651 ABBVIE INC. $20.48 03/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104959653 ABBVIE INC. $30.05 06/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105371656 AstraZeneca Pharmaceuticals LP $20.84 03/19/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1115900897 Amgen Inc. $17.90 10/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116614750 GlaxoSmithKline, LLC. $19.37 03/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117619230 Amgen Inc. $17.16 02/01/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117619232 Amgen Inc. $19.60 04/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117619234 Amgen Inc. $15.05 08/15/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1124045049 Vifor Pharma, Inc. $18.96 03/14/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1129445576 Esperion Therapeutics, Inc. $16.19 02/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135393187 Lilly USA, LLC $15.97 04/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1145103608 Mallinckrodt Hospital Products Inc. $17.95 06/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1151092641 Phathom Pharmaceuticals, Inc. $17.80 05/23/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.